These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 18222155)
1. Telithromycin and the FDA: implications for the future. Shlaes DM; Moellering RC Lancet Infect Dis; 2008 Feb; 8(2):83-5. PubMed ID: 18222155 [No Abstract] [Full Text] [Related]
2. Telithromycin: the perils of hasty adoption and persistence of off-label prescribing. Gleason PP; Walters C; Heaton AH; Schafer JA J Manag Care Pharm; 2007 Jun; 13(5):420-5. PubMed ID: 17605513 [TBL] [Abstract][Full Text] [Related]
3. Limit Ketek to pneumonia, experts advise: advisers urge black-box warning. Young D Am J Health Syst Pharm; 2007 Jan; 64(2):124-5. PubMed ID: 17215452 [No Abstract] [Full Text] [Related]
4. FDA and the safe and appropriate antibiotic use of fluoroquinolones. Tillotson GS Lancet Infect Dis; 2016 Mar; 16(3):e11-2. PubMed ID: 26973315 [No Abstract] [Full Text] [Related]
5. Telithromycin and acute liver failure. Graham DJ N Engl J Med; 2006 Nov; 355(21):2260-1. PubMed ID: 17124030 [No Abstract] [Full Text] [Related]
6. Risk of hepatotoxicity associated with the use of telithromycin: a signal detection using data mining algorithms. Chen Y; Guo JJ; Healy DP; Lin X; Patel NC Ann Pharmacother; 2008 Dec; 42(12):1791-6. PubMed ID: 19033479 [TBL] [Abstract][Full Text] [Related]
7. Ketek--the FDA perspective. Soreth J; Cox E; Kweder S; Jenkins J; Galson S N Engl J Med; 2007 Apr; 356(16):1675-6. PubMed ID: 17442912 [No Abstract] [Full Text] [Related]
8. Telithromycin: visual disorders, myasthenia. Case fatalities: this macrolide has a negative risk-benefit balance; its use not justified. Prescrire Int; 2008 Apr; 17(94):66. PubMed ID: 18516818 [No Abstract] [Full Text] [Related]
9. The FDA and the case of Ketek. Ross DB N Engl J Med; 2007 Apr; 356(16):1601-4. PubMed ID: 17442902 [No Abstract] [Full Text] [Related]
10. Telithromycin for the treatment of acute exacerbations of chronic bronchitis. Fogarty C; Zervos M; Tellier G; Aubier M; Rangaraju M; Nusrat R Int J Clin Pract; 2005 Mar; 59(3):296-305. PubMed ID: 15857326 [TBL] [Abstract][Full Text] [Related]
13. Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases. Brinker AD; Wassel RT; Lyndly J; Serrano J; Avigan M; Lee WM; Seeff LB Hepatology; 2009 Jan; 49(1):250-7. PubMed ID: 19085949 [TBL] [Abstract][Full Text] [Related]
14. Telithromycin use and spontaneous reports of hepatotoxicity. Dore DD; DiBello JR; Lapane KL Drug Saf; 2007; 30(8):697-703. PubMed ID: 17696582 [TBL] [Abstract][Full Text] [Related]
15. Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world. Echols RM Ann N Y Acad Sci; 2011 Dec; 1241():153-61. PubMed ID: 22191531 [TBL] [Abstract][Full Text] [Related]
16. [Pharmacoeconomic analysis of patients with acute exacerbation of chronic bronchitis treated with telithromycin or cefuroxime-axetil]. Rubio-Terrés C; Cots JM; Domínguez-Gil A; Herreras A; Sánchez Gascón F; Chang J; Trilla A Rev Clin Esp; 2004 Nov; 204(11):567-73. PubMed ID: 15511402 [TBL] [Abstract][Full Text] [Related]
17. Effective integration of medical and pharmacy claims to better protect patient safety--a long road yet to travel. Curtiss FR J Manag Care Pharm; 2007 Jun; 13(5):429-30. PubMed ID: 17605515 [No Abstract] [Full Text] [Related]
18. Apparent anaphylactoid reaction after treatment with a single dose of telithromycin. Bottenberg MM; Wall GC; Hicklin GA Ann Allergy Asthma Immunol; 2007 Jan; 98(1):89-91. PubMed ID: 17225726 [TBL] [Abstract][Full Text] [Related]
19. Re: Acute bacterial rhinosinusitis--a review of US treatment guidelines. Randall DA Otolaryngol Head Neck Surg; 2007 Apr; 136(4):681; discussion 682. PubMed ID: 17418279 [No Abstract] [Full Text] [Related]